All posts tagged "orthovita"

  • Biologics
    Orthovita shareholders sue to stop $316 million Stryker buyout

    Shareholders of Orthovita Inc. (NSDQ: VITA), a Malvern, Pa.-based orthopedic biologics maker, are suing over a proposed $316...

  • Biologics
    Stryker Launches Tender Offer

    Orthopedic devices giant Stryker Corp (SYK – Analyst Report) has commenced its $3.85 per share tender offer for its previously announced acquisition of orthobiologic and biosurgery products maker Orthovita Inc (VITA – Snapshot Report). The Michigan-based devices maker struck a deal on May 16 to buy Pennsylvania-based Orthovita for $316 million in cash. Per the agreement,...

  • Biologics
    Stryker Announces Definitive Agreement to Acquire Orthovita, Inc. for $3.85 Per Share in Cash

    Kalamazoo, Michigan – May 16, 2011- Stryker Corporation (NYSE:SYK) announced today a definitive agreement to acquire Orthovita,...

  • Biologics
    Orthovita Launches the Aliquot™ Directional Bone Tamp

    MALVERN, Pennsylvania, Wednesday, April 13, 2011 – Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today the launch of the Aliquot™ Directional Bone Tamp. The Directional Bone Tamp, a channel creation device that allows safe and targeted placement of Cortoss™ Bone Augmentation Material into the vertebral body, expands the procedural...

  • Biologics
    Orthovita Announces Presentation of Clinical Results Evaluating Vitagel™ Surgical Hemostat in Reducing Blood Loss During Primary Unilateral Total Knee Arthroplasty

    MALVERN, Pennsylvania, Monday, April 11, 2011 – Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce that Michael Bloomfield, M.D., of Cleveland Clinic, presented results of a study entitled “Prospective Randomized Evaluation of a Collagen/Thrombin and Autologous Platelet Hemostatic Agent During Total Knee Arthroplasty” on Friday, April 8,...

  • Biologics
    Orthovita Gets FDA Clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

    Orthovita, Inc., an orthobiologics and biosurgery company, said that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. In a release, the Company noted: Orthovita...

  • Biologics
    Orthovita Receives FDA Clearance for Vitoss™ Bioactive Foam-2X Bone Graft Substitute

    MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects...

  • Financial
    Orthovita Announces 2010 Third Quarter Product Sales

    MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, today announced that product sales for the third quarter of 2010 were $23.3 million, a 5% increase over product sales of $22.3 million in the third quarter of 2009. For the first nine months of 2010, product sales increased 4% to...

  • Biologics
    Orthovita Announces Presentation of Cortoss 24-Month Pivotal Study Results at the 25th Annual Meeting of the North American Spine Society

    MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce that Hyun W. Bae, M.D., of The Spine Institute at Saint John’s Health Center in Santa Monica, California, will present an abstract entitled, “Correlation of Early Pain and Long-Term Functional Results from a Multi-Center, Prospective, Randomized, Controlled...

  • Spine
    Medtronic Spinal & Biologics’ Reign in the US Vertebral Compression Fracture Treatment Market Threatened as New Players Emerge

    WALTHAM, Mass., July 22 /PRNewswire/ — According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Medtronic Spinal & Biologics, which has dominated the US vertebral compression fracture treatment market for over 10 years, now faces its stiffest competition as new entrants and new products enter the US market. In...

  • Financial
    Orthovita Reports 2009 Fourth Quarter and Year-End Financial Results

    MALVERN, Pa., Mar 10, 2010 (BUSINESS WIRE) — –Fourth quarter 2009 operating income of $385,000 compared to an operating loss of $670,000 in fourth quarter 2008; full year 2009 operating loss was $1.1 million compared to an operating loss of $9.2 million in 2008 –Fourth quarter 2009 net loss of $291,000, or...

  • Spine
    Orthovita to Present at the Canaccord Adams Musculoskeletal Conference

    MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ:VITA), an orthobiologics and biosurgery company, announced today that it will present at the Canaccord Adams Musculoskeletal Conference in New Orleans. Antony Koblish, President and Chief Executive Officer of Orthovita, is scheduled to present on Tuesday, March 9, at 8:00 a.m. Central Time, at the Sheraton New Orleans Hotel,...

  • Spine
    Has Orthovita’s Fight Finally Ended?

    Article preview reprinted from IN VIVO –  December/January, 2010 Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another...

OrthoSpineNews is a publication run by Ortho Spine Companies which includes other brands like The De Angelis Group, Ortho Sales Partners, OrthoEx and Surg.io

Our desire is to provide valuable content to the industry we love in an easy to read manner.

Copyright © 2018 OrthoSpineNews.

Themed By teapots